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Mesenchymal stem cells (MSCs) have the ability to
differentiate into osteoblasts, chondroblasts,
adipocytes, and even myoblasts. Most studies have
focused on finding MSCs in different parts of the
body for medical treatment. Every joint structure,
including bone, joint fat, articular cartilage, and
synovium, potentially contains resident MSCs.
Recently, a progenitor cell population has been found
in synovial fluid and showed similarities with both
bone marrow and synovial membrane MSCs. Synovial
fluid MSCs have been studied in healthy persons and
osteoarthritic patients in order to explore its potential
for treatment of some orthopedic disorders. Here, we
briefly review the current knowledge on synovial fluid
MSCs, their origin, relation to some orthopedic
diseases, and future applications.conditions.Introduction
Osteochondral defects may progress to osteoarthritis
(OA), causing pain and disability [1]. Many attempts
have been made to treat cartilage defects and prevent
joint degeneration. Surgical options include microfracture,
autologous chondrocyte implantantion, and osteochondral
autograft or allograft, but no treatment has been able to re-
store the natural structure and composition of cartilage [2].
Thus, unfortunately, until today, no treatment has been
proved to stabilize, reverse, or prevent OA development.* Correspondence: eduardobsousa@globo.com
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2014In the last decades, stem cells have proven to be useful
in tissue regeneration and treatment of many diseases.
Mesenchymal stem cells (MSCs) have been identified in
both healthy and diseased cartilage, and their potential
in cartilage regeneration has been studied in vivo [3,4].
Recent findings have led to a discussion that synovial
fluid (SF) fibroblasts displayed activated phenotypes,
which mediated cartilage destruction through inflam-
mation in the synovium [5]. SF fibroblasts have been
demonstrated to be closely related in phenotype to bone
marrow (BM) MSCs [6]. This suggests that normal SF
has a resident MSC population that increases during
OA [7]. MSCs were also found in higher number in SF
from knees after meniscal injury than in normal ones
[8]. However, the origin and role of these SF MSCs have
not yet been determined. The goal of this review is to
provide the current knowledge on SF MSCs, their origin,
and relation to other joint tissues in normal and arthriticSynovial membrane, synovial fluid, and synovial
fluid mesenchymal stem cells
The synovial membrane (SM) is a specialized mesenchy-
mal tissue lining the spaces of diarthrodial joints, bursae,
and tendon sheaths [9]. SM includes two layers: the intima
inner layer, composed of one or two sheets of macro-
phages or fibroblast-like synoviocytes, and the subintima
outer layer, composed of two to three layers of synovio-
cytes lying over loose connective tissue rich in fibroblasts,
secreting collagen, and other extracellular matrix proteins.
The subintima layer has few macrophages and lympho-
cytes, fat cells, and blood vessels, which provide nutrients
to the SM and the adjacent avascular cartilage [9-11].
Cells from the SM intimal layer secrete the SF, which
provides articular cartilage lubrication, chondrocyte activ-
ity, and nutrition. The synovial intima is composed of two
different cell types: type A and B synoviocytes [12]. TypeLtd. The licensee has exclusive rights to distribute this article, in any medium, for 12
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identify them as coming from macrophage and fibroblast
lineages, respectively [13].
Type A synoviocytes (synovial macrophages) stand
round the upper part of synovial lining, whose surface is
covered by microvilli and microplicae, like typical macro-
phage structures [12]. These cells proliferate in inflamma-
tory conditions. Type A SM cells are positive for CD163
and CD68, but not for CD14+/lo, and present non-specific
esterase activity [9]. Macrophages are not only in the in-
timal but also in the subintimal layers of SM, deriving
from circulating monocytes originated from the BM [9].
Synovial intimal fibroblasts express the surface marker
CD55, which is used to distinguish them from synovial
macrophages [9]. Under pathological conditions, synovial
macrophages may contribute to cartilage destruction due
to prolonged production of pro-inflammatory cytokines or
through the formation of osteophytes by the release of the
growth factors transforming growth factor-beta (TGF-β) 3 and
bone morphogenetic protein (BMP)-2 and BMP-4 [14,15].
Type B synoviocytes (synovial fibroblasts), which are
fibroblast-like cells, express the class II major histocom-
patibility molecule, which confers a key role in antigen
presentation in early phases of immune responses in the
SM. Type B synoviocytes are found further from the
synovial lining and produce mainly the glycosaminogly-
can hyaluronic acid (HA), one of the main constituents
of cartilage extracellular matrix, involved with cell sig-
naling by binding to cell receptor CD44 [11]. In this re-
gard, SM intimal type B synoviocytes possess high uridine
diphosphate (UDP) glucose dehydrogenase (UDPGD) ac-
tivity, which converts UDP-glucose to UDP-glucuronate,
essential for HA synthesis [9]. In addition, these SM cells
produce lubricin, which is responsible for protecting the
surface of articular cartilage [12].
In normal conditions, HA and lubricin are not filtered
and play a role in joint lubrication due to HA’s high mo-
lecular weight, which provides SF viscosity [12]. Lubricin
helps in joint lubrication, thus reducing pathologic de-
position of proteins over the articular cartilage surface
[12,16,17], and small molecules such as growth factors
and cytokines instead easily diffuse in the SF [12]. These
results showed that SM also acts as a semipermeable
membrane that controls molecules traffic and the com-
position of the SF [2,12].
Characterization of synovial fluid mesenchymal
stem cells
MSCs have been defined following the studies by
Friedenstein and colleagues [18] and Pittenger and col-
leagues [19] as BM cell components of non-hematopoietic
origin. In this regard, BM spindle-shaped adherent cells
with heterogeneous appearance were described. In the
1980s, other investigators established that those cellswere multipotent, able to differentiate in osteoblasts,
chondroblasts, adipocytes, and, in certain conditions,
myoblasts [17,20]. MSCs were also identified in several
organs as cells that have the function of replacing local
cells lost in physiological turnover or repairing and re-
generating injured tissues [21].
Microscopic analysis revealed cell aggregates entrapped
in fibrin, typical of inflammatory SF. Intact pieces of
synovium have been documented, but synovial cells
were not well characterized in vitro. Some findings
demonstrated the presence of clonogenic and multipo-
tent MSCs in the SF of both young animals and human
joints not affected by arthritis. Since these fragments
are significantly hyperplastic, they seem to be a result of
avulsion from weakened synovium because of a lack of
nutrients [3]. These fragments are probably not related
to the origin of SF MSCs.
According to the International Society for Cytotherapy,
MSCs must be able to adhere to plastic material and
expand when cultured in vitro. In addition, MSCs must
express the surface markers CD73, CD90, and CD105
and be negative for the expression of CD45, CD34,
CD14, CD11b, CD79α, CD19, and HLA-DR surface
molecules. Moreover, MSCs must show the ability to
differentiate into three lineages of mesenchymal cells:
osteoblasts, chondroblasts, and adipocytes [22].
Comparison among MSCs isolated from BM and adi-
pose tissue (AT) and SM or synovium showed that these
cells do not express hematopoietic markers, such as
CD11b [22,23], CD14 [23,24], CD19 [22],CD31 [23,24],
CD34 [22,23], CD45 [22-25], CD79α [22], CD117 [23],
and HLA-DR [22], but must have the expression of
CD13 [24], CD29 [25], CD40 [26], CD44 [24,25], CD49e
[27], CD73 [23,24], CD90 [24,25], CD105 [23-25],
CD147 [25], CD166 [23,24], Notch1 [27], and STRO-1
[23] on their surfaces (Table 1). Although the cell marker
CD271 is expressed in AT and BM MSCs, its expression
seems to be negative in healthy SM MSCs [24]. However,
CD271 was demonstrated to be expressed in the SM of
patients with OA [28].
SF MSCs show high expression of hialuronan receptors
CD44 and UDPGD, required for hialuronan synthesis.
During synovial joint development, prior to cavitation,
CD44 is expressed in the interzone and the articular sur-
faces. Conversely, UDPG activity is increased in the articu-
lar surfaces but is lowered in the interzone. HA free and
bound are found at this time in the interzone. After cavita-
tion, synovium and articular surfaces bind CD44 to HA.
This process facilitates tissue separation and helps cre-
ate a functional joint cavity [33]. In cultures enriched
with CD90 cells, levels of chondrogenesis were higher
than in culture fractions depleted of CD90 [26]. The
CD90 receptor was demonstrated to interact with integ-
rins, tyrosine kinases, growth factors, and cytokines,
Table 1 Mesenchymal stem cell markers for cells derived from synovial membrane, cartilage, fat pad, bone marrow,
and synovial fluid
Tissue Positive markers Negative markers References
Synovial membrane CD90, CD105, CD147, and CD44 CD34, CD45, CD117, and CD31 De Bari et al. [17] (2001),
Sakaguchi et al. [29] (2005)
Cartilage CD49e, Notch1, CD90, and STRO-1 antigen Williams et al. [27] (2010),
Alsalameh et al. [30] (2004)
Fat pad CD13, CD29, CD44, CD90, and CD105 CD34, CD56, CD271, and STRO1 Khan et al. [31] (2012)
Bone marrow CD13, CD29, CD44, CD90, and CD105 CD34 and CD45 Barry and Murphy [32] (2013)
Synovial fluid CD40, CD44, CD73, CD90, CD 105, and CD 166 CD11b, CD34, CD45, and CD271 Boeuf and Richter [24] (2010),
Krawetz et al. [26] (2012)
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sion, apoptosis, proliferation, and migration. However,
the heterogeneity of synovial cells has not been well
described [26].
Functional studies showed that SF MSCs were distinct
from BM MSCs; SF MSCs form a pool of highly clono-
genic cells with chondrogenic potential, whereas BM
MSCs are very heterogeneous. This fact suggested that SF
MSCs were not derived from BMMSCs but from adjacent
synovium [7]. This corroborates the findings from another
study, which showed that SF MSCs seemed to be closer
to synovium MSCs than to BM MSCs [34]. Another
study revealed that intra-articular bleeding soon after
anterior cruciate ligament rupture leads to a shift of SF
MSCs by expression of cytokines and chemokines that
recruit MSCs from elsewhere. It showed that the num-
ber of SF MSCs increased after the lesion, suggesting
that SF MSCs originated neither from BM nor from
circulating MSCs but probably from the synovium or
cartilage [35,36].
Therapeutic potential for synovial membrane
stem cells
Synovial inflammation is present in early OA and is
possibly the trigger of the cascades leading to articular
destruction but may also be the focus of repairing re-
sponses from progenitor cells [32]. In patients with OA,
there is a decrease on the cartilage extracellular matrix
components type II collagen fibers and aggrecan pro-
teoglycan, the latter of which is formed by HA associ-
ated with distinct sulfated glycosaminoglycans, the
main one of which is chondroitin sulfate. This condition
leads to a reduction in the absorption of mechanical
forces [16]. Moreover, SF lubricin decreases in OA, con-
tributing to lower articular cartilage lubrication [37]. In
addition, higher levels of vascular endothelial growth
factor were demonstrated in SF of patients with OA
versus rheumatoid arthritis, indicating that angiogenesis
might play a role in cartilage degeneration. Also, the ac-
tivation of pro-inflammatory cytokines, such as IL-6,
IL-8, interferon-gamma, and monocyte chemoattractant
protein-1, of human chondrocytes by OA patient SFsupports the pro-inflammatory process in the develop-
ment of OA [38]. Moreover, elevated IL-15 levels are
found in the synovium of patients with early knee OA,
providing evidence of activation of innate immunity
within SM [39].
Immature articular cartilage contains a population of
progenitor cells responsible for its appositional growth.
Notch 1 is present in the chondrocytes of the surface
zone articular cartilage, determining the proliferation of
these cells. Thus, Notch-1 signaling has been associated
with healthy cartilage progenitors [32,40]. Overexpression
of Notch-1, Notch-2, RbpJ, and Hes1 has been observed
in chondrocyte differentiation [41]. Besides, Notch-1-
positive cells were found in greater numbers in cartilage
clusters from patients with OA than in control experi-
ments [32]. Cartilage clusters are a typical phenotype of
OA and may result from dedifferentiation and prolifera-
tion of resident chondrocytes, although migration of
progenitor cells cannot be discarded [32].
SM has an intrinsic ability of regeneration given its re-
covery after sinovectomy [35], suggesting that SM could
act as a cell source for cartilage repair [25]. Synovial
chondromatosis is a rare proliferative condition of un-
known etiology. It evoked a possible role of SM MSCs
in the production of multiple intrasynovial cartilaginous
nodules [42]. MSCs isolated from the SM, called SM-
derived stem cells [17], or synovial mesenchymal pro-
genitor cells [43] were shown to share the same pheno-
typic and functional properties of BM MSCs [44]. The
presence of MSCs in the synovial lining leads to ques-
tions on their origin. They could have been recruited
from blood that penetrates synovial tissue or originated
from BM that connects to intra-articular space. The
possible role of MSCs in synovial lining is related to
healing potential of tissues originated from the meso-
derm. Furthermore, their cells may be involved in early
stages of osteoarticular diseases. BM MSCs and SM
MSCs express different genes, including activin A,
which is upregulated in BM MSCs [44]. Unlike BM
MSCs, MSCs derived from SM maintain proliferation
rate and colony-forming potential regardless of the age
of the patient [43,45].
Figure 1 Morphological aspects of synovial fluid mesenchymal stem cells isolated from (A) healthy persons and (B) patients with
osteoarthritis. Cell cluster (arrowhead) is observed in synovial fluid mesenchymal stem cells from patients with osteoarthritis.
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tiality inherent to single cells. Single cell-derived MSCs be-
come heterogenous during expression. Non-clonal plastic
adherent synovial MSCs consist of a uniform cell popu-
lation [46]. Koga and colleagues [47] demonstrated that
transplanted synovium-derived MSCs were altered ac-
cording to the microenvironments in rabbits.
Cells derived from human synovium were shown to
have the greatest chondrogenesis potential among the
mesenchymal tissue-derived cells, representing a possible
source for cartilage repair. Synovium and AT MSCs were
demonstrated to be superior in terms of adipogenesis.
In addition, MSCs derived from BM, synovium, or peri-
osteum were shown to be superior in osteogenesis [29].
Studies revealed that synovial MSCs precultured with
autologous human serum were able to differentiate into
chondrocytes in vitro but that their chondrogenic po-
tential was lower than that of the cells maintained with
fetal bovine serum [48]. In addition, synovial cells de-
rived from older human osteoarthritic donors could be
reprogrammed to pluripotent cells in alginate culture
by stimulation of BMP-2 or BMP-7 in dexamethasone-
and serum-free conditions [49]. These results showed
that SM has a therapeutic potential for treatment of
chondral defects using in vitro experiments, since human
autologous serum increased the proliferative potential of
SM MSCs through platelet-derived growth factors signal-
ing activation [48]. MSC-like cells from SM can be found
in healthy and OA cartilage [29,49].
BM cells imbedded in growth factors such as TGF-β,
BMP, and insulin-like growth factors (IGFs) have an im-
portant role in the repair of cartilage defects [50]. Mem-
bers of the BMP family, mainly BMP-7 and IGF-1, have
demonstrated in vitro ability to stimulate chondrogene-
sis [23]. The problem remains in the complexity of the
signaling pathways involved in chondrogenesis stimu-
lated by cell-to-cell contact [23]. The chemokine profile
of healthy and arthritic SF could contribute to the recruit-
ment of human mesenchymal progenitor from the sub-
chondral bone [51]. Human SF from healthy persons and
OA and rheumatoid arthritis donors contains differentlevels of chemokines such as CCL22, Ccl27, CXCL5, and
CXCL12, inhibiting migration of human subchondral
mesenchymal progenitors. However, other chemokines
found in SF, such as CCL2, CCL24, and CXCL7, had no
effect on the attraction of mesenchymal progenitor cells
[51]. The number of MSCs recruited by SF from rheuma-
toid arthritis patients is lower than from OA or normal
donors, suggesting that the chemotactic factors contribute
to the attraction of progenitors [50]. We have observed
distinct morphological aspects of cells derived from SF of
healthy persons and OA patients (Figure 1). It was re-
ported that SF MSC levels in normal knee joints increased
sevenfold in early OA [7]. SF MSCs probably participate
in homeostasis, remodeling, and tissue repair through the
replacement of cells. We can speculate that these cells are
liable to re-establish the imbalance between OA catabol-
ism and joint anabolism.Conclusions
SF seems to have a role in attracting MSCs whether
from BM or other sources on the synovial joint. This
role is crucial for maintaining joint homeostasis. Ex-
ploring these mechanisms seems to be the way to find a
potential treatment for cartilage degeneration. Additional
improvement should be pursued to achieve more efficient
therapy for patients with OA. Moreover, the anti-
proliferative and anti-migratory function in SF MSCs
in patients with OA could be used to reduce cartilage
destruction by SF MSCs. Cartilage bioengineering in-
volves cell differentiation and extracellular matrix syn-
thesis in a stratified conformation that replicates native
cartilage. We believe that more basic, translational, and
clinical studies involving SF MSCs will lead to improve-
ments in OA treatment.
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